- Home
- NBTX vs OCCI Comparison
NBTX vs OCCI Comparison
Compare NBTX & OCCI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- OCCI
- Stock Information
- Founded
- NBTX 2003
- OCCI N/A
- Country
- NBTX France
- OCCI United States
- Employees
- NBTX N/A
- OCCI N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- OCCI Trusts Except Educational Religious and Charitable
- Sector
- NBTX Health Care
- OCCI Finance
- Exchange
- NBTX Nasdaq
- OCCI Nasdaq
- Market Cap
- NBTX 178.7M
- OCCI 146.8M
- IPO Year
- NBTX 2020
- OCCI N/A
- Fundamental
- Price
- NBTX $3.61
- OCCI $6.19
- Analyst Decision
- NBTX Strong Buy
- OCCI
- Analyst Count
- NBTX 1
- OCCI 0
- Target Price
- NBTX $12.00
- OCCI N/A
- AVG Volume (30 Days)
- NBTX 13.1K
- OCCI 115.8K
- Earning Date
- NBTX 04-23-2025
- OCCI 12-11-2023
- Dividend Yield
- NBTX N/A
- OCCI 24.32%
- EPS Growth
- NBTX N/A
- OCCI N/A
- EPS
- NBTX N/A
- OCCI N/A
- Revenue
- NBTX $45,220,186.00
- OCCI N/A
- Revenue This Year
- NBTX N/A
- OCCI N/A
- Revenue Next Year
- NBTX N/A
- OCCI $10.19
- P/E Ratio
- NBTX N/A
- OCCI N/A
- Revenue Growth
- NBTX 526.17
- OCCI N/A
- 52 Week Low
- NBTX $2.76
- OCCI $5.47
- 52 Week High
- NBTX $7.51
- OCCI $10.15
- Technical
- Relative Strength Index (RSI)
- NBTX 52.08
- OCCI 22.24
- Support Level
- NBTX $3.32
- OCCI $6.52
- Resistance Level
- NBTX $3.77
- OCCI $7.17
- Average True Range (ATR)
- NBTX 0.21
- OCCI 0.22
- MACD
- NBTX 0.01
- OCCI -0.08
- Stochastic Oscillator
- NBTX 60.55
- OCCI 10.50
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About OCCI OFS Credit Company Inc.
OFS Credit Co Inc is a non-diversified, closed-end management investment company. Its investment objective is to generate current income, with a secondary objective to generate capital appreciation. The company invests in floating rate credit instruments and other structured credit investments, including; collateralized loan obligation (CLO) debt and subordinated (i.e., residual or equity) securities; traditional corporate credit investments, including leveraged loans and high yield bonds; opportunistic credit investments, including stressed and distressed credit situations and long/short credit investments; and other credit-related instruments.